Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt ...

Researchers recommended that regulators consider mandating head-to-head trials comparing next-in-class and against existing in-class agents when possible.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

HealthDay News — The US Department of Health and Human Services has announced a major initiative to reform the organ transplant system. This action follows an investigation by the Health Resources and ...

HealthDay News — Small-group professional coaching can reduce physician burnout rates by up to nearly 30%, according to a study published online July 11 in the Journal of General Internal Medicine.

Six or 9 months of bedaquiline, delamanid, linezolid, and clofazimine was not noninferior to longer standard of care.